Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs)
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors · Source last updated 2017-03-29
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
From start of study drug administration up to 90 days after the last dose of MEDI3617
What was measured
Laboratory evaluations were performed, including hematology and serum chemistry. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to laboratory abnormalities were recorded and reported.
Analysis population: Safety population included all participants who received treatment with MEDI3617.
Groups in this outcome
MEDI3617 SINGLE AGENT TOTAL
Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
MEDI3617 + BEVACIZUMAB Q2W TOTAL
Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
MEDI3617 + PACLITAXEL TOTAL
Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
MEDI3617 SINGLE AGENT TOTAL
42
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
16
MEDI3617 + BEVACIZUMAB Q2W TOTAL
38
MEDI3617 + PACLITAXEL TOTAL
13
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
7
Reported measurements
Hematology: Anemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
5
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
3
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
2
Not reported
Not reported
Not reported
Not reported
Hematology: Leukopenia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
2
Not reported
Not reported
Not reported
Not reported
Hematology: Neutropenia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
3
Not reported
Not reported
Not reported
Not reported
Hematology: Thombocytopenia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
2
Not reported
Not reported
Not reported
Not reported
Hematology: White blood cell count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
SerChem: Alanine aminotransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Aspartate aminotransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Blood alkaline phosphatase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Blood creatinine increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Blood lactate dehydrogenase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Blood potassium increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Blood triglycerides increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Blood urea increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Gamma-glutamyltransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hyperglycaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hyperkalaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hypertriglyceridaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hyperuricaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hypoalbuminaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hypocalcaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hypoglycaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
SerChem: Hypokalaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
3
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
SerChem: Hypomagnesaemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
3
Not reported
Not reported
Not reported
Not reported
SerChem: Hyponatremia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
MEDI3617 SINGLE AGENT TOTAL
0
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
2
Not reported
Not reported
Not reported
Not reported
MEDI3617 + BEVACIZUMAB Q2W TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + PACLITAXEL TOTAL
1
Not reported
Not reported
Not reported
Not reported
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
2
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
2
title
Hematology: Anemia
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
2
title
Hematology: Leukopenia
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
3
title
Hematology: Neutropenia
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
2
title
Hematology: Thombocytopenia
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
title
Hematology: White blood cell count decreased
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
0
title
SerChem: Alanine aminotransferase increased
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
2
group Id
OG003
value
1
group Id
OG004
value
0
title
SerChem: Aspartate aminotransferase increased
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
0
title
SerChem: Blood alkaline phosphatase increased
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
1
group Id
OG002
value
2
group Id
OG003
value
1
group Id
OG004
value
0
title
SerChem: Blood creatinine increased
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
title
SerChem: Blood lactate dehydrogenase increased
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
title
SerChem: Blood potassium increased
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
0
group Id
OG004
value
0
title
SerChem: Blood triglycerides increased
denoms
counts
group Id
OG000
value
42
group Id
OG001
value
16
group Id
OG002
value
38
group Id
OG003
value
13
group Id
OG004
value
7
units
Participants
description
Laboratory evaluations were performed, including hematology and serum chemistry. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to laboratory abnormalities were recorded and reported.
groups
description
Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
id
OG000
title
MEDI3617 SINGLE AGENT TOTAL
description
Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
id
OG001
title
MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL
description
Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
id
OG002
title
MEDI3617 + BEVACIZUMAB Q2W TOTAL
description
Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
id
OG003
title
MEDI3617 + PACLITAXEL TOTAL
description
Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
id
OG004
title
MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL
param Type
NUMBER
population Description
Safety population included all participants who received treatment with MEDI3617.
reporting Status
POSTED
time Frame
From start of study drug administration up to 90 days after the last dose of MEDI3617
title
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs)
Triangle